The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase family and have been implicated in tumorigenesis. One isoform in particular, JNK2a, has been shown to be frequently activated in primary brain tumors, to enhance several tumorigenic phenotypes and to increase tumor formation in mice. As JNK is frequently activated in non-small cell lung carcinoma (NSCLC), we investigated the role of the JNK2a isoform in NSCLC formation by examining its expression in primary tumors and by modulating its expression in cultured cell lines. We discovered that 60% of the tested primary NSCLC tumors had three-fold higher JNK2 protein and two-to three-fold higher JNK2a mRNA expression than normal lung control tissue. To determine the importance of JNK2a in NSCLC progression, we reduced JNK2a expression in multiple NSCLC cell lines using short hairpin RNA. Cell lines deficient in JNK2a had decreased cellular growth and anchorageindependent growth, and the tumors were four-fold smaller in mass. To elucidate the mechanism by which JNK2a induces NSCLC growth, we analyzed the JNK substrate, signal transducer and activator of transcription 3 (STAT3). Our data demonstrates for the first time that JNK2a can regulate the transcriptional activity of STAT3 by phosphorylating the Ser727 residue, thereby regulating the expression of oncogenic genes, such as c-Myc. Furthermore, reintroduction of JNK2a2 or STAT3 restored the tumorigenicity of the NSCLC cells, demonstrating that JNK2a is important for NSCLC progression. Our studies reveal a novel mechanism in which phosphorylation of STAT3 is mediated by a constitutively active JNK2 isoform, JNK2a.
Introduction
The c-Jun N-terminal kinases (JNK) members of the mitogen-activated protein kinase (MAPK) family can mediate apoptosis or proliferation through the phosphorylation of transcription factors (Yeager et al., 1995; Butterfield et al., 1997; Arbour et al., 2002; Lee et al., 2008) . Several lines of evidence indicate that JNK is important in promoting cell growth and tumorigenesis (Bode and Dong, 2007; Bogoyevitch and Arthur, 2008) . First, enhanced JNK activity promotes tumorigenesis in cells (Berner et al., 1999) . Second, several tumor cell lines have been reported to have constitutive JNK activity and enhanced expression (Xu et al., 1996; Rodrigues et al., 1997) . Lastly, inhibition of JNK expression reduces glial tumor formation (Potapova et al., 2000) .
There are three distinct JNK genes (JNK1, JNK2 and JNK3) and 10 different splicing isoforms. The JNK signaling pathway is activated by numerous stimuli, resulting in several seemingly contradictory cellular responses (Cheng et al., 2002) . For example, JNK1 activity is associated with apoptosis and tumor suppression, whereas JNK2 activity can stimulate cell proliferation and tumor formation (Chen et al., 2001; Yang et al., 2003) . Consequently, each JNK gene and individual isoform most likely mediate different functions depending on the stimulus (Bogoyevitch, 2006) .
Several findings suggest that one particular JNK2 isoform, JNK2a, has a significant role in tumorigenesis. The JNK2a isoform is unique, possessing the ability to autophosphorylate and consequently autoactivate. It has been shown to have enhanced expression in primary glial tumors (Cui et al., 2005; Tang et al., 2006) , and this constitutively active isoform has been found to increase tumorigenic phenotypes and enhance tumor formation in nude mice (Tang et al., 2006; Nitta et al., 2008) . Thus far, the JNK2a isoform has only been linked to glial tumorigenesis; however, it may also be involved in nonsmall cell lung carcinoma (NSCLC) progression. Recent studies show that NSCLC tumors and cell lines have constitutively active JNK and that the inhibition of JNK activity decreased NSCLC cell growth (Khatlani et al., 2007) . Furthermore, reduced expression of JNK2, but not JNK1, decreased tumorigenic phenotypes in NSCLC cells (Berner et al., 1999) . On the basis of these reports we hypothesized that the constitutively active JNK2a isoform may be an important component of NSCLC tumorigenesis.
In this study we sought to determine whether JNK2a has a role in NSCLC tumorigenesis. We examined the expression of this particular JNK isoform in primary NSCLC tumors and used genetic and biochemical approaches to modulate JNK2a expression and activity in cultured NSCLC cells. We found that the majority of NSCLC tumors have increased JNK2a expression. To determine whether this JNK isoform has a direct role in NSCLC formation, we generated multiple NSCLC cell lines deficient in JNK2a, using retroviruses to introduce short hairpin RNA (shRNA). We discovered that the reducing JNK2a expression decreased tumorigenic phenotypes and tumor formation in mice. To elucidate the mechanism by which JNK2a induces NSCLC tumorigenesis, we studied a well-known oncogene and JNK substrate, STAT3. Reducing JNK2a expression in a NSCLC cell line yielded a significant reduction in STAT3 phosphorylation at the Ser727 residue and a decrease in STAT3 transcriptional activity. Furthermore, reintroducing JNK2a2 or STAT3 rescued the tumorigenicity of NSCLC cells deficient in JNK2a demonstrating that the JNK2a isoform is directly involved in NSCLC progression. Overall our findings show that JNK2a can induce NSCLC tumor formation by regulating the activity of oncogenic downstream substrates, such as STAT3.
Results

The expression of JNK2a is enhanced in NSCLC tumors
We initially analyzed 10 primary NSCLC tumors for JNK expression. 60% of these samples had two-to three-fold increased levels of JNK2, but not JNK1 or JNK3, as compared with a representative normal lung sample ( Figure 1a , Supplementary Figure 1A , Supplementary Table 1 ). Presently available commercial JNK antibodies can only be used to distinguish the three JNK genes (JNK1, JNK2 and JNK3) and not specific isoforms, so we designed isoform-specific quantitative reverse transcriptase PCR (QRT-PCR) primers to differentiate between the JNK isoforms. Despite having very similar amino acid sequences, the JNK isoforms have sufficiently divergent nucleotide sequences that enabled us to differentiate between these isoforms. To monitor JNK expression, we compared the tumor samples to two representative normal lung samples that were extracted from similar regions of the lung. Using QRT-PCR, we discovered that the JNK2a isoform had two-to three-fold higher mRNA expression in NSCLC tumors, whereas the very similar JNK2b isoform had no significant change (Figure 1b) . It is interesting that the QRT-PCR analysis also revealed that the JNK2a-isoform is the predominant JNK2 isoform expressed, having significantly higher mRNA expression compared with JNK2b (data not shown). We extended our QRT-PCR analysis to seven additional primary tumors and discovered that 70% had two-to three-fold higher JNK2a mRNA expression (Supplementary Figure 1B) .
Reduction of endogenous JNK2a in NSCLC cell lines using shRNAs To determine whether JNK2a is directly involved in lung tumorigenesis, we studied the tumorigenic effects of JNK2a in two NSCLC cell lines, NCI-H2009 and HCC-827. Previous reports indicated that these two cell lines have constitutively active JNK that enhances cell proliferation, but did not specify which isoform was responsible (Khatlani et al., 2007) . We analyzed the significance of the constitutively active JNK2a in these cell lines, hypothesizing that JNK2a is responsible for inducing lung tumorigenesis and, therefore, reducing endogenous JNK2a should ameliorate the tumorigenic potential of these cells. To test this hypothesis, we utilized the divergent nucleotide sequences in the JNK isoforms to introduce shRNA specific for a nucleotide sequence unique to the JNK2a gene (shJNK2a RT Nitta et al analysis revealed that the HCC-827 shJNK2a cells had a six-fold decrease in JNK2 compared with the uninfected or shScrambled control cells, whereas the NCI-H2009 shJNK2a cells had a seven-fold reduction (Figure 2a ). JNK1 and JNK3 levels were similar in all the tested cell lines indicating that the knockdown was specific to the JNK2 gene. As a further control, we also analyzed another MAPK protein, ERK1/2 and determined that our shRNA specifically targeted the JNK pathway. QRT-PCR analysis verified that the JNK2a isoform was being specifically knocked down as the HCC-827 shJNK2a cells had a 3.5-fold reduction in JNK2a expression, whereas the H2009 shJNK2a cells had a four-fold decrease (Figure 2b) . Consistently, the expression of JNK1, JNK3 and the highly similar JNK2b isoform were not altered.
JNK2a in NSCLC tumorigenesis
We subsequently examined whether JNK activity was reduced in our shJNK2a cell lines. Western analysis showed that the cells deficient in JNK2a had reduced JNK2 phosphorylation compared with the control cell (c) H2009 cells were serum starved for 24 h and then stimulated with 500 mM sorbitol. The protein samples were separated using 4-20% SDS-PAGE and detected with the specified antibodies. **-represents the JNK2 isoform. The arrow indicates the JNK1 isoforms.
RT Nitta et al lines, whereas the phosphorylation levels of the other JNK proteins were not altered ( Figure 2a ). In addition, when we stimulated JNK activity with sorbitol, we discovered that the H2009 shJNK2a cells had reduced JNK2 and c-Jun phosphorylation compared with the uninfected control cells (Figure 2c ). Together these results suggest that the reducing JNK2a expression in H2009 cells not only reduced the overall levels of JNK phosphorylation but also reduced the ability of JNK to phosphorylate downstream substrates, such as c-Jun.
JNK2a is necessary for tumorigenic phenotypes in NSCLC cells in vitro
On the basis of the previous studies showing that a constitutively active JNK2a isoform is expressed in human gliomas, we determined whether decreasing JNK2a expression could decrease or prevent NSCLC tumor formation (Tsuiki et al., 2003) . We discovered that the shJNK2a-treated cells had a significantly slower growth rate compared with the control cells and a reduced ability to grow in soft agar .
To verify these findings, we extended our analysis to two additional NSCLC cell lines, NCI-H1650 and HCI-H1975. These cell lines were not shown to have constitutive JNK activity, but JNK inhibitors decreased their cell growth (Khatlani et al., 2007) . Consistent with our previous findings, we were able to specifically reduce JNK2a expression five-fold (Supplementary Figure JNK2a is important for NSCLC tumorigenicity in NOD/SCID mice We extended our study by testing the effects of reducing JNK2a on tumor formation, predicting that reducing endogenous JNK2a expression would reduce the tumorigenicity of the NSCLC cells. To this end, we subcutaneously injected the H2009 Uninfected, shScrambled, or shJNK2a cells into the hind limb of athmyic mouse. After 7 weeks, we removed the tumors and discovered the mice injected with the control cells formed tumors that were B0.8 g, whereas the shJNK2a cells yielded tumors that were significantly smaller in mass, only B0.2 g (Figure 3d ). We verified that the smaller tumors had reduced JNK2a expression through western and QRT-PCR analysis (data not shown).
JNK2a forms a complex with STAT3
One of the primary functions of JNK is to phosphorylate and activate transcription factors. One intriguing substrate of JNK is STAT3 (Lim and Cao, 1999) . STAT3 is a well-established oncogene that is known to regulate pro-survival and pro-proliferative signaling in NSCLC cells (Alvarez et al., 2006) . To elucidate the mechanism by which JNK2a achieves its tumorigenic effects, we determined whether JNK2a could form a complex with STAT3. 3xFlag tagged JNK2a2 (a JNK2a isoform) was transfected into H2009 cells and co-immunoprecipitation experiments were performed. We discovered that the 3xFlag JNK2a2 was able to co-immunoprecipitate with endogenous STAT3 (Figure 4a ). We extended our analysis by determining whether the formation of the JNK2-STAT3 complex was decreased in cells lacking JNK2a.
To this end, we conducted co-immunoprecipitation experiments using antibodies specific for endogenous STAT3 or JNK2 (as there are no commercially available JNK2a antibodies) in the H2009 shJNK2a cells. We discovered that the absence of JNK2a significantly decreased the amount of STAT3 that co-immunoprecipitated with JNK2 suggesting that JNK2a is an important component of the JNK-STAT3 complex (Figure 4b ).
JNK2a can regulate the phosphorylation and activity of STAT3 in NSCLC cells
To ascertain whether JNK2a is involved in regulating STAT3 activity, we looked at the ability of JNK2a2 to phosphorylate serine 727 of STAT3. Phosphorylation of this residue has been shown to enhance cell proliferation and tumorigenesis (Qin et al., 2008; Yeh et al., 2009) . We initially conducted in vitro kinase assays using bacterially expressed and purified JNK2a2 and STAT3. Wild-type JNK2a2 enhanced the phosphorylation of Ser727 three-fold compared with STAT3 alone ( Figure 5a ). As JNK can phosphorylate serine/threonie and tyrosine residues, we tested whether the JNK2a2 phosphorylation of STAT3 was non-specific by analyzing the phosphorylation of tyrosine 705. As Tyr705 phosphorylation was not altered, we concluded that JNK2a2 can only phosphorylate Ser727 (Figure 5a ).
To verify that JNK2a2 is directly responsible for Ser727 phosphorylation, we also analyzed a kinase dead mutation, K55R. Consistent with previous findings, we discovered that the inactive K55R mutant did not autophosphorylate, and did not alter the phosphorylation of Ser727 (Nitta et al., 2008) . We extended our analysis to H2009 shJNK2a cells and discovered that Ser727 phosphorylation was decreased four-fold compared with the shScrambled cells (Figure 5b ). It is interesting that the phosphorylated Ser727 produced a strong nuclear signal in the shScrambled cells, yet this nuclear accumulation was significantly impaired in the H2009 shJNK2a cells (Figure 5c ). To be transcriptionally active, STAT3 must translocate to the nucleus and recent reports suggest that phosphorylation of Ser727 has an important role in this translocation (Bhattacharya et al., 2005; Qin et al., 2008) . To determine whether the decrease in STAT3 Ser727 phosphorylation and nuclear accumulation significantly altered STAT3 transcriptional activity, we analyzed the expression of a STAT3 regulated gene, c-MYC. c-MYC expression is enhanced in NSCLC, is necessary for NSCLC metastasis and has been shown to be transcriptionally upregulated upon Ser727 phosphorylation (Broers et al., 1993; Gazzeri et al., 1994; Yakut et al., 2003; Qin et al., 2008; Rapp et al., 2009) . H2009 shJNK2a cells had three-fold less c-MYC protein compared with the control cells and 2.5-fold less mRNA demonstrating that the loss of JNK2a significantly reduced expression of a STAT3-regulated oncogene (Figure 5b ).
To determine whether JNK2a is important for STAT3 transcriptional activity, we performed reporter gene assays that measured STAT3-dependent transcriptional activity in the H2009 shJNK2a cells. A fireflyluciferase-based reporter plasmid that contains four copies of the STAT3 enhancer element (pSTAT3-TALuc) or the empty vector (pTA-Luc) was co-transfected into the NSCLC cells with a Renilla-luciferase reporter plasmid (pRL-CMV). The Renilla-luciferase plasmid was used as an internal control for the normalization of STAT3 reporter activity. The cells were serum starved for 24 h after which both firefly and Renilla luciferase levels were measured. We discovered that the Uninfected and shScrambled cells transfected with pSTAT3-TA-Luc had a two-to three-fold increase in luciferase activity compared with the pTA-Luc transfected cells, whereas the H2009 shJNK2a cells had no significant change suggesting that cells deficient in JNK2a had reduced basal activity of STAT3. To verify that pSTAT3-TA-Luc was specific for STAT3 activity, we stimulated the cells with epidermal growth factor (EGF) that was shown to enhance STAT3 transcriptional activity through phosphorylation of Ser727 ( pSTAT3-TA-Luc transfected cells had a 2.5-fold increase in luciferase activity, whereas the cells transfected with pTA-Luc control vector had no change (Figure 5d ). It is interesting that, even with EGF stimulation the H2009 shJNK2a cells had 2.5-fold less luciferase activity compared with the control cells showing that the absence of endogenous JNK2a significantly decreased, but did not completely abolish, STAT3 transcriptional activity (Figure 5d ). To verify that cells deficient in JNK2a had reduced expression of STAT3-regulated genes under EGF stimulation, we analyzed c-MYC mRNA levels and determined that EGF stimulation increased c-MYC expression three-fold in the control cells. The H2009 shJNK2a cells had two-fold less expression under serum deprivation conditions and a three-fold decrease with EGF stimulation (Figure 5d ). Together these findings show that JNK2a is important for STAT3 transcriptional activity and regulation of STAT3-dependent genes through the phosphorylation of Ser727.
Reintroduction of JNK2a2 or STAT3 rescues tumorigenic phenotypes in NSCLC cells
To directly establish the significance of JNK2a in NSCLC tumorigenesis we stably introduced a JNK2a2 mutant that is resistant to the shJNK2a knockdown (JNK2a2res) into the H2009 shJNK2a cells. It is surprising that the introduction of the yellow fluorescent protein (YFP)-tagged JNK2a2res increased untagged JNK2 expression. This is most likely due to either proteolytic cleavage of the YFP tag or competition with shRNA. Western analysis showed that YFP-JNK2a2res restored phosphorylation of STAT3 Ser727 and the expression of c-Myc (Figure 6a ). In addition, JNK2a2res restored cell proliferation and anchorage independence confirming the importance of JNK2a in NSCLC tumor progression (Figures 6b and c) . To determine whether JNK2a induces tumorigenic phenotypes occurs through phosphorylation of Ser727, we stably overexpressed wild-type STAT3, a phosphodeficient mutant (S727A) or a phospho-mimetic mutant (S727E) in H2009 shJNK2a cells. Expression of the exogenous wild-type STAT3 and S727E mutant restored S727 phosphorylation along with c-MYC expression, whereas there were no changes with the expression of the phospho-deficient mutant S727A (Figure 6a ). It is interesting that the wild-type STAT3 restored cell proliferation 80% and anchorage-independent growth 85%, whereas the S727A mutant phenocopied the shJNK2a vector control cells and the S727E phenocopied the shScrambled control cells (Figures 6b and c) . This finding suggests that, although the JNK2a-STAT3 complex has an important role in NSCLC progression, there are other downstream substrates of JNK2a that may also partially contribute to NSCLC tumorigenesis.
Discussion
In this study, we investigated the role of JNK2a in NSCLC tumorigenesis by examining its expression in JNK2a in NSCLC tumorigenesis RT Nitta et al primary NSCLC tumors and by modulating its expression in cultured NSCLC cells. We showed for the first time that a constitutively active JNK isoform has increased expression in the majority of primary NSCLC tumors tested. To directly determine the significance of JNK2a in NSCLC progression, we used retroviruses to specifically reduce endogenous JNK2a in multiple NSCLC cell lines. Each cell line with decreased levels of JNK2a had significantly reduced JNK activity that resulted in the decreased tumorigenic phenotypes, such as decreased cellular growth, anchorage-independent growth and tumor formation in NOD/SCID mice. To elucidate the mechanism by which JNK2a induces NSCLC formation, we analyzed a well-known oncogene and JNK substrate STAT3. Our data show that JNK2a isoforms can interact with and regulate STAT3 transcriptional activity by phosphorylating Ser727. In addition, we demonstrated that the reintroduction of JNK2a2 or STAT3 restored the tumorigenic phenotypes in cells deficient in JNK2a, demonstrating the importance of JNK2a in NSCLC progression.
JNK2a regulation of oncoproteins or tumor suppressors
Our study suggests that JNK2a has a major role in NSCLC tumorigenesis by regulating the activity of the oncoprotein STAT3. Although the role of JNK2a in other tumors is still unknown, our preliminary work suggests that JNK2a has a direct role in glioblastoma multiforme (GBM) tumorigenesis (Tang et al., 2006) . We have discovered that reducing endogenous JNK2a expression in two GBM cell lines, U87-MG and U251, decreased tumorigenic phenotypes and tumor formation in mice (data not shown). Yet, JNK2a is not a universal oncogene as reducing JNK2a expression in SCLC cell lines did not alter cell growth or anchorage-independent growth (Supplementary Figures 3A-D) . Consequently, to fully understand the role of JNK2a in various cancers it is important to study the relationship between JNK2a and its substrates. Previous research has already shown that JNK2a can phosphorylate oncoproteins such as eIF4E, Akt (Tang et al., 2006) , and b-catenin (Wu et al., 2008) . Other oncogenic JNK2a substrates, such as Sirt1 (Ford et al., 2008) and Ras (Shair et al., 2007) , have been shown to be phosphorylated by JNK2 specifically. The JNK2 isoforms have also been associated with phosphorylation and regulation of the activity of tumor suppressors. Recently, p53 was shown to directly interact with and be phosphorylated by JNK2, whereas the well-known JNK substrate, c-Jun, was discovered to inhibit p53 activity (Maeda and Karin, 2003; Oleinik et al., 2007) . Our study, in conjunction with previous reports, suggests that the JNK2a has a key role in the regulation of oncoproteins and tumor suppressors. Further research should be conducted to identify additional JNK2a substrates that may regulate tumorigenesis.
Phosphorylation of STAT3 at S727 in NSCLC tumorigenesis Activation of the STAT3 transcription factor has been implicated in cellular transformation and tumor progression. The oncogenic activities of STAT3 were first observed when an overexpressed, constitutively active STAT3-induced tumor formation in nude mice (Bromberg et al., 1999) . Subsequent biochemical analysis revealed that STAT3 could promote cell growth and cell survival in tumor cells by transcriptionally upregulating genes, such as c-MYC, BCL-2, cyclin D1 and VEGF (Gao and Bromberg, 2006) . STAT3 has also been shown to be constitutively active in a variety of solid and hematological tumors, including breast, prostate, ovarian and lung cancers (Kortylewski et al., 2005) . In particular, STAT3 activity has been closely linked to NSCLC tumorigenesis. For example, two independent reports observed increased expression or enhanced phosphorylation of STAT3 in the majority of NSCLC tumors (Haura et al., 2005; Achcar Rde et al., 2007) . Moreover, the inhibition of STAT3 activity using G-quartet oligodeoxynucleotides decreased cell growth and reduced tumor formation in NSCLC bearing nude mice (Weerasinghe et al., 2007; Zhang et al., 2007) . STAT3 activation and the subsequent increase in transcriptional activities have been linked to the phosphorylation of two different STAT3 residues: tyrosine 705 and serine 727. The function of Tyr705 phosphorylation has been carefully studied and reports show that it leads to STAT3 homodimerization through its SH2 domain, which enhances translocation to the nucleus and activation of STAT3 target genes (Chung et al., 1997) . The role of Ser727 phosphorylation is less clear. Phosphorylation of Ser727 was shown to enhance STAT3 homodimerization and DNA binding or to solely affect transcriptional activity (Wen et al., 1995; Zhang et al., 1995) . Although the mechanism by which Ser272 phosphorylation regulates STAT3 activity remains unknown, Ser727 was found to induce prostate and lung tumorigenesis independent of Tyr705 phosphorylation by enhancing the transcription of pro-proliferative genes, such as c-MYC (Qin et al., 2008; Yeh et al., 2009) . In addition, Ser727 has been implicated with the ability of STAT3 to transform cells in a Ras-dependent manner by targeting STAT3 to the mitochondria (Gough et al., 2009) . Subsequently, many researchers have tried to identify the STAT3 serine kinase(s) hoping to identify new therapeutic targets.
JNK phosphorylation of STAT3
The STAT3 carboxyl-terminal Ser727 residue is located within a consensus site of MAPK phosphorylation. MAPK proteins are serine-and threonine-specific kinases and have been shown to phosphorylate Ser727. For example, one report showed that ERK, but not JNK1, could phosphorylate Ser727 in vitro and in vivo (Chung et al., 1997) . It is interesting that, a subsequent study demonstrated that JNK1 has the ability to phosphorylate Ser727 when activated by ultraviolet light or by an upstream kinase, MEKK7 (Lim and Cao, 1999) . These seemingly contradictory results could be due to the differential activation of JNK1. Unlike JNK2a, JNK1 is not constitutively active and, therefore, stimuli must be used to activate this JNK protein (Tsuiki et al., 2003) . As JNK2a has the unique ability to autophosphorylate, and consequently autoactivate, we studied the relationship between this JNK isoform and STAT3 phosphorylation. Our discovery that JNK2a can regulate STAT3 activity by directly phosphorylating STAT3 at Ser727 is critical in understanding the therapeutic potential of targeting this pathway. Significant research has been conducted to identify potent serine kinases for STAT3. By identifying a serine kinase that enhances tumorigenicity in NSCLC cells, we have discovered a novel therapeutic target for NSCLC tumors.
Materials and methods
Cell culture and transfection
The NSCLC cell lines NCI-H2009, HCC-827, NCI-H1650 and NCI-H1975 (from American Type Culture Collection, Manassas, VA, USA), were cultured in RPMI-1640 media supplemented with 10% fetal bovine serum and 2 mM-L-glutamine. Cells were transfected using TransIT LT1 (Mirus, Madison, WI, USA) according to the manufacturer's protocol.
Protein analysis and immunoprecipitations
Protein extracts from cells were harvested and immunoblotted as previously described (Nitta et al., 2007) . The following antibodies were used for immunoblotting or immuoprecipitations: green fluorescent protein (Roche, Palo Alto, CA, USA), phosphorylated JNK (Cell Signaling Technology, Danvers, MA, USA), JNK2 (Cell Signaling), c-Myc (Santa Cruz Biotechnlogy, Santa Cruz, CA, USA), JNK1 (Santa Cruz Biotechnlogy), JNK3 (Upstate, Billerica, MA, USA), actin (Chemicon, Billerica, MA, USA), STAT3 (B&D Bioscience, San Jose, CA, USA), phospho STAT3 S727 (Cell Signaling Technology), phospho STAT3 Y705 (Cell Signaling Technology) and Flag (Sigma, St Louis, MO, USA). Chemiluminescence signals were quantitated using NIH Image J (National Institutes of Health, Bethesda, MD, USA). Immunoprecipitations were conducted as previously described (Nitta et al., 2006) .
Retroviral infections
Retroviral small inhibitory RNA (shRNA) constructs were generated by ligating annealed oligonucleotides (JNK2a 5 0 -AAGGTTGTGTGATATTCCA-3 0 or scrambled 5 0 -GTAAACAAAGCAATGTATA-3 0 ) into pSuper.retroPuro (Oligoengine, Seattle, WA, USA). Retroviral infections were carried out as previously described (Xie et al., 1997) . 36 h after infection, the cells were selected using 5 mg/ml of puromyocin for 3 days. JNK2a2res and STAT3 were reintroduced into H2009 shJNK2a cells using the pMXIH retroviral vector as previously described (Xie et al., 1997) . The JNK2a2 mutant resistant to shJNK2a was generated by mutating the following nucleotides: T666C and G669C.
Cell growth analysis NSCLC-infected cells were plated in six-well plates (5 Â 10 5 cells per well) and cultured in RPMI-1640 media supplemented with 1% fetal bovine serum, 2 mM L-glutamine, and 100 units per ml penicillin/streptomycin. The numbers of live cells were counted daily by means of trypan blue exclusion assay. Experiments were done in triplicate and results are expressed as mean ± s.d.
Soft agar assay NSCLC cells were plated in six-well plates (3 Â 10 5 cells per well), suspended in RPMI-1640 as previously described (Tang et al., 2006) . The presence of colonies was scored after 10 days using Genetools software (Syngene, Frederick, MA, USA). Experiments were done in triplicate and results are expressed as mean±s.d.
In vivo tumor formation in NOD/SCID mice 2 Â 10 6 cells of NCI-H2009 cells were treated and subcutaneously injected into the hind limbs of six to eight-week old mice as previously described (Tang et al., 2006) . Around 7 weeks after injection the tumors were weighed.
QRT-PCR analysis
Total RNA from each cell line was extracted using Trizol reagent (Promega, Madison, WI, USA) according to the manufacturer's protocol. The reverse transcription and quantitative PCR (qPCR) were carried out using the Brilliant II Syber Green QRT-PCR Master Mix Kit according to the manufacturer's protocol (Stratagene, La Jolla, CA, USA). Primers were designed specifically for the JNK2a, JNK2b, JNK1 or JNK3 genes and the specificity was verified by sequencing. Their sequences were: JNK2a (forward), 5 0 -GCGTGCACTAACTTCATGATGAC-3 0 ; JNK2a (reverse), 5 0 -GCAACCCACTGACCAGATATCAAC-3 0 ; JNK2b (forward), 5 0 -GCACCCTGAAGATCCTTGAC-3 0 ; JNK2b (reverse), 5 0 -CGGGAACAGGACTTTATGGA-3 0 ; JNK1 (forward), 5 0 -GGCTCAGGAGCTCAAGGAATAG-3 0 ; JNK1 (reverse), 5 0 -GATTCTGAAATGGTCGGCTTAG-3 0 ; and JNK3 (forward), 5 0 -CATAGTTTGTGCCGCGTATG-3 0 ; JNK3 (reverse), 5 0 -GGCATCCATCAGTTCCATTAC-3 0 ; c-Myc (forward) 5 0 -TGAGGAGACACCGCCCA-3 0 ; c-Myc (reverse) 5 0 -AACAT CGATTTCTTCCTCA-3 0 ; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (forward) 5 0 -GTCCACCACCCTGTTGCTG TA-3 0 ; GAPDH (reverse) 5 0 -ACCACAGTCCATGCCATC-3 0 . All samples were normalized to GAPDH. Fresh-frozen NSCLC tumors and adjacent normal tissues were obtained from the Biosample Repository at Fox Chase Cancer Center (Philadelphia, PA, USA). All specimens were accrued and evaluated under institutional review board (IRB)-approved protocols.
In vitro kinase assay 1 mg of the fusion protein was incubated in kinase buffer at 30 1C for 30 min as previously described (Tang et al., 2006) . Reactions were terminated by adding protein loading buffer and boiling for 5 min.
Luciferase assay
Using TransIT LT1 (Mirus), NCI-H2009-infected cells were transiently co-transfected with pSTAT3-TA-Luc vector (Clontech, Mountain View, CA, USA) and pRL-CMV (Promega). 24 h after transfection the cells were serum starved for 24 h, and subsequently stimulated with EGF (250 ng/ml). The firefly and Renilla luciferase activities of the stimulated cells were measured using the Dual-Luciferase Reporter Assay System (Promega). The values obtained from the NCI-H2009-uninfected cells were used to normalize the relative STAT3 activity.
Indirect immunofluorescence
Immunofluorescence was performed on formaldehyde-fixed cells followed by a methanol permeabilization as previously described (Lee et al., 2004) . The phospho STAT3 S727 antibody (Cell Signaling Technology) was used. Images were taken using Leica SP2 AOBS confocal microscope. Images
